CVSI · CV Sciences, Inc. · Executive Compensation
$0.01
0.00 (-10.71%)
At close · Oct 20
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The Company's financial operating results and accumulated deficit, amongst other factors, raise substantial doubt about the Company's ability to continue as a going concern. The Company will continue to work towards increasing revenue and operating cash flows to meet its future liquidity requirements. However, there can be no assurance that the Company will be successful in any capital-raising efforts that it may undertake, and the failure of the Company to raise additional capital could adversely affect its future operations and viability.”View the 10-Q filed Aug 13, 2026
Market Cap
$2.26M
Shares
225.83M
Volume · Oct 20
2.36M
Avg daily vol (3M)
542.99K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $418,995 |
| Joerg Grasser | Chief Financial Officer | $307,986 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $457,667 |
| Joerg Grasser | Chief Financial Officer | $343,322 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $403,152 |
| Joerg Grasser | Chief Financial Officer | $273,041 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $298,983 |
| Joerg Grasser | Chief Financial Officer | $210,471 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $1,206,814 |
| Joerg Grasser | Chief Financial Officer | $645,690 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $863,079 |
| Joerg Grasser | Chief Financial Officer | $482,650 |
| Dr. Douglas MacKay | Senior Vice President of Scientific and Regulatory Affairs | $336,380 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Joseph Dowling | Chief Executive Officer | $2,766,471 |
| Joerg Grasser | Chief Financial Officer | $1,382,450 |
| Dr. Douglas MacKay | Senior Vice President of Scientific and Regulatory Affairs | $1,245,986 |
| Michael Mona | Former Chairman and Chief Executive Officer | — |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Michael Mona | Former Chairman and Chief Executive Officer | $7,227,562 |
| Joerg Grasser | Chief Financial Officer | $816,511 |
| Joseph Dowling | Chief Executive Officer | $748,959 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Bill McCorkle | Director | Appointed | 2026-06-04 |
| Joseph Dowling | Director | Appointed | 2026-06-04 |
| Dr. Jamie Corroon | Director | Appointed | 2026-06-04 |
| Bill McCorkle | Director | Appointed | 2023-06-05 |
| Joseph Dowling | Director | Appointed | 2023-06-05 |
| Dr. Jamie Corroon | Director | Appointed | 2023-06-05 |
| William McCorkle | director | Appointed | 2022-10-25 |
| Dr. Joseph C. Maroon | member of the Board of Directors of the Company | Resigned | 2022-07-27 |
| Dr. Jamie Corroon Jr., ND, MPH | director on the Company's Board of Directors | Appointed | 2022-07-27 |
Leadership
- Joseph Dowling CEO, Board Member
- Michael Mona CEO
- Joerg Grasser CFO
- Beth Altman Board Member
- Bill McCorkle Board Member
- Dr. Jamie Corroon Board Member
- Dr. Jamie Corroon Jr., ND, MPH Board Member
- Dr. Paul Blake Board Member
- James McNulty Board Member
- Terri Funk Graham Board Member
- William McCorkle Board Member